0% found this document useful (0 votes)
32 views24 pages

Disturbances in Emotional Experience:: Behavioral and Psychological Symptoms of Dementia Psychopathological Features

The document discusses behavioral and psychological symptoms of dementia including disturbances in emotional experience, delusions and abnormal thought content, perceptual disturbances, disturbances in motor function, circadian rhythms, and appetite and eating behavior. It then covers specific features of common dementias like Alzheimer's disease, dementia with Lewy bodies, vascular dementia, and frontotemporal dementia. Finally, it discusses treatment options and delirium.

Uploaded by

Riya Gupta
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
0% found this document useful (0 votes)
32 views24 pages

Disturbances in Emotional Experience:: Behavioral and Psychological Symptoms of Dementia Psychopathological Features

The document discusses behavioral and psychological symptoms of dementia including disturbances in emotional experience, delusions and abnormal thought content, perceptual disturbances, disturbances in motor function, circadian rhythms, and appetite and eating behavior. It then covers specific features of common dementias like Alzheimer's disease, dementia with Lewy bodies, vascular dementia, and frontotemporal dementia. Finally, it discusses treatment options and delirium.

Uploaded by

Riya Gupta
Copyright
© © All Rights Reserved
We take content rights seriously. If you suspect this is your content, claim it here.
Available Formats
Download as PDF, TXT or read online on Scribd
You are on page 1/ 24

NCD

Behavioral and psychological symptoms of dementia

PSYCHOPATHOLOGICAL FEATURES

● Disturbances in Emotional Experience:


● Symptoms of depression frequently masked by
dementia.
● Inability to express typical feelings of sadness,
unhappiness, and hopelessness.
● Prominent symptoms include anhedonia, somatic
concerns, anxiety, and fear.
● Apathy is common and mistaken for depression,
characterized by lack of motivation without dysphoria.
● Elated mood, ranging from hypomania to severe mania,
can occur.
● Affective (or mood) lability characterized by rapid
emotional shifts.

● Delusions and Abnormal Thought Content:


● Delusional ideas, typically less complex and organized
than in non-demented psychotic patients.
● Common delusional themes involve suspicion,
abandonment, and misidentification.
● Examples include paranoia about people entering the
home, belief that one's spouse is an impostor, and
accusations of conspiracy.
● Severe depression can lead to delusional thoughts
involving guilt, worthlessness, reference, and
persecution.
● Perceptual Disturbances:
● Perceptual disturbances can manifest as illusions or
hallucinations.
● Visual hallucinations, particularly common in dementia
with Lewy bodies, often involve well-formed images of
animals or people.

● Disturbances in Motor Function:


● Motor disturbances include reduced or increased motor
activity.
● Motor retardation presents as slowed movements and
speech, while motor hyperactivity involves increased
energy level and rapid movements or speech.
● Agitation encompasses inappropriate verbal, vocal, or
motor activity and can be non-aggressive or aggressive.

● Circadian Rhythms:
● Sleep pattern changes are prevalent in individuals with
dementia.
● Changes may include hypersomnia, insomnia,
sleep-wake cycle reversal, fragmented sleep, and rapid
eye movement sleep behavior disorder.
● Factors contributing to sleep disturbances include pain,
medications, and stimulants.

● Appetite and Eating Behavior:


● Appetite changes can be quantitative (anorexia or
hyperphagia) or qualitative (preference for particular
foods).
● Preference for sweets is common in fronto-temporal
dementia.
● Most dementia patients experience weight loss, possibly
due to hypermetabolism and hormonal disturbances.

Specific features of common dementias

● Alzheimer's Disease:
● Prominent symptoms include apathy, agitation, depression, anxiety,
delusions, and irritability.
● Less common are hallucinations and elation.
● Three basic behavioral syndromes predominate: few abnormalities,
psychosis, and mood disorder.
● Agitation and apathy may coexist with other behavioral symptoms.
● Neurobiological changes include lower metabolism and perfusion in
frontal and temporal lobes.
● Agitation and psychosis correlate with a high burden of neurofibrillary
tangles.
● Genotypes associated with behavioral disturbances involve
serotoninergic, cholinergic, and dopaminergic systems.
● Dementia with Lewy Bodies:
● High prevalence of neuropsychiatric symptoms, often prominent at
presentation.
● Complex visual hallucinations are recurrent, accompanied by illusions
and misidentification phenomena.
● Visual hallucinations linked to profound visuoperceptual dysfunction
and reduced uptake in occipital areas.
● High numbers of Lewy bodies in temporal lobe and amygdala; deficits
in cortical acetylcholine.
● Apathy, anxiety, delusions, and depression are common and persist
over time.
● Rapid Eye Movement Sleep Behavior Disorder (RBD) history suggests
dementia with Lewy bodies.
● Vascular Dementia:
● Neuropsychiatric symptoms as common and important as in
Alzheimer's disease.
● Mood symptoms like depression, emotional lability, and apathy are
particularly common.
● Strong relation between cerebrovascular disease, especially
white-matter lesions, and depression.
● Other symptoms include anxiety disorders and psychosis.
● Frontotemporal Dementia:
● Unique behavioral symptoms: disinhibition, apathy, and elation; often
precede memory deterioration.
● Compulsive disorders with stereotypical and ritualized behaviors.
● Changes in appetite with carbohydrate cravings and dietary changes.
● Behavioral symptoms correlate with involvement of right hemisphere
frontal and temporal-lobe structures.

Treatment

● Non-pharmacological Interventions:
● Behavioral therapies, environmental changes, exercise,
and music therapy are effective.
● Educational interventions for carers help reduce
symptom escalation and improve relationships.
● Carers may need interventions for depression, anxiety,
and substance use to reduce morbidity.
● Pharmacological Treatment:
● Antipsychotics, mood stabilizers, antidepressants,
anxiolytics, and sedative-hypnotics commonly used.
● Limited randomized controlled trials for psychotropic
drugs in dementia; evidence supporting effectiveness is
limited.
● Atypical antipsychotics approved in some regions for
agitation and psychosis in dementia.
● However, no drug specifically approved for any BPSD
indication by the US FDA.
● Prescription of psychotropic drugs widespread despite
lack of systematic evidence and regulatory approval.
● Antipsychotic Medications:
● Atypical antipsychotics most studied; several trials show
efficacy in reducing agitation and psychosis.
● Conventional antipsychotics also effective but associated
with increased rates of parkinsonism and tardive
dyskinesia.
● Risperidone and olanzapine, commonly used for BPSD,
associated with increased risk of cerebrovascular
events.
● Caution required in the use of antipsychotic drugs due to
increased risk of mortality.
● Anticonvulsant Medications:
● Used as second-line treatments in patients resistant to
antipsychotic drugs.
● Associated with adverse events such as sedation and
gait instability.
● Modest efficacy shown in small randomized controlled
trials, but not consistently effective compared to placebo.
● Antidepressant Medications:
● Widely used despite limited evidence for superiority over
placebo.
● Selective serotonin reuptake inhibitors commonly used
due to favorable side-effect profile.
● Sertraline shown to reduce mood symptoms in patients
with Alzheimer's disease.
● Combined serotonin and noradrenalin reuptake inhibitors
represent alternative but poorly studied option.
● Benzodiazepines:
● Generally not advised in people with dementia due to
susceptibility to side-effects and potential exacerbation of
behavioral disinhibition.
● Exception is low-dose clonazepam for management of
rapid eye movement sleep-behavior disorder.
● Treatment of Cognitive Symptoms:
● Cholinesterase inhibitors (donepezil, galantamine,
rivastigmine) may reduce behavioral symptoms in
Alzheimer's disease.
● Memantine, an N-methyl-D-aspartate receptor
antagonist, can also reduce BPSD in Alzheimer's
disease.
● Limited evidence-based information guides treatment
choices for BPSD management in dementia, relying on
expert guidance and personal prescribing experience.

DELIRIUM

Delirium is characterized by an acute decline in both the level of


consciousness and cognition with particular impairment in attention.

A life-threatening, yet potentially reversible disorder of the central nervous


system (CNS), delirium often involves perceptual disturbances, abnormal
psychomotor activity, and sleep cycle impairment.

Delirium is often underrecognized by health care workers. Part of the


problem is that the syndrome has a variety of other names.

The hallmark symptom of delirium is an impairment of consciousness,


usually occurring in association with global impairments of cognitive
functions.

Abnormalities of mood, perception, and behavior are common psychiatric


symptoms. Tremor, asterixis, nystagmus, incoordination, and urinary
incontinence are common neurological symptoms.

Classically, delirium has a sudden onset (hours or days), a brief and


fluctuating course, and rapid improvement when the causative factor is
identified and eliminated, but each of these characteristic features can
vary in individual patients.
ETIOLOGY

The major causes of delirium are CNS disease (e.g., epilepsy),


systemic disease (e.g., cardiac failure), and either intoxication or
withdrawal from pharmacological or toxic agents

In treating delirium, the primary goal is to treat the underlying cause.

The other important goal of treatment is to provide physical, sensory, and


environmental support.

Physical support is necessary so that delirious patients do not get into


situations in which they may have accidents.

Patients with delirium should be neither sensory deprived nor overly


stimulated by the environment. They are usually helped by having a friend
or relative in the room or by the presence of a regular sitter.

Familiar pictures and decorations; the presence of a clock or a calendar;


and regular orientations to person, place, and time help make patients with
delirium comfortable.
Psychiatric and Neurological Changes
Personality.

Changes in the personality of a person with dementia are especially


disturbing for their families. Preexisting personality traits may be
accentuated during the development of a dementia. Patients with
dementia may also become introverted and seem to be less concerned
than they previously were about the effects of their behavior on others.
Persons with dementia who have paranoid delusions are generally hostile
to family members and caretakers. Patients with frontal and ternporal
involvement are likely to have marked personality changes and may be
irritable and explosive.
Hallucinations and Delusions.

An estimated 20 to 30 percent of patients with dementia (primarily patients


with dementia of the Alzheimer's type) have hallucinations, and 30 to 40
percent have delusions, primarily of a paranoid or persecutory and
unsystematized nature, although complex, sustained, and
well-systematized delusions are also reported by these patients. Physical
aggression and other forms of violence are common in demented patients
who also have psychotic symptoms.

Mood.

In addition to psychosis and personality changes, depression and anxiety


are major symptoms in an estimated 40 to 50 percent of patients with
dementia, although the full syndrome of depressive disorder may be
present in only 10 to 20 percent. Patients with dementia also may exhibit
pathological laughter or crying-that is, extremes of emotions-with no
apparent provocation.

Cognitive Change.

In addition to the aphasias in patients with dementia, apraxias and


agnosias are common. Other neurological signs that can be associated
with dementia are seizures, seen in approximately 10 percent of patients
with dementia of the Alzheimer's type and in 20 percent of patients with
vascular dementia, and atypical neurological presentations, such as
nondominant parietal lobe syndromes. Primitive reflexes, such as the
grasp, snout, suck, tonic-foot, and palmomental reflexes, may be present
on neurological examination, and myoclonic jerks are present in 5 to 10
percent of patients.

Patients with vascular dementia may have additional neurological


symptoms, such as headaches, dizziness, faintness, weakness, focal
neurological signs, and sleep disturbances, possibly attributable to the
location of the cerebrovascular disease. Pseudobulbar palsy, dysarthria,
and dysphagia are also more common in vascular dementia than in other
dementing conditions.

Catastrophic Reaction.

Patients with dementia also exhibit a reduced ability to apply what Kurt
Goldstein called the "abstract attitude." Patients have difficulty
generalizing from a single instance, forming concepts, and grasping
similarities and differences among concepts. Furthermore, the ability to
solve problems, to reason logically, and to make sound judgments is
compromised.

Goldstein also described a catastrophic reaction marked by agitation


secondary to the subjective awareness of intellectual deficits under
stressful circumstances. Persons usually attempt to compensate for
defects by using strategies to avoid demonstrating failures in intellectual
performance; they may change the subject, make jokes, or otherwise
divert the interviewer.

Lack of judgment and poor impulse control appear commonly, particularly


in dementias that primarily affect the frontal lobes. Examples of these
impairments include coarse language, inappropriate jokes, neglect of
personal appearance and hygiene, and a general disregard for the
conventional rules of social conduct.

Sundowner Syndrome.

Sundowner syndrome is characterized by drowsiness, confusion, ataxia,


and accidental falls. It occurs in older people who are overly sedated and
in patients with dementia who react adversely to even a small dose of a
psychoactive drug. The syndrome also occurs in demented patients when
external stimuli, such as light and interpersonal orienting cues, are
diminished.
What are the symptoms?
There are a variety of symptoms that may indicate major neurocognitive
disorder. Some common symptoms, according to the Diagnostic and
Statistical Manual of Mental Disorders, fifth edition (DSM-5), include:

● a significant decline in one or more cognitive domains, compared to


your previous abilities
● the cognitive change impairs your independence in daily life, such as
paying bills, managing money, or taking medications
● the cognitive change does not exclusively occur as part of a delirium
— a sudden state of confusion
● the cognitive decline cannot be better explained by another mental
health condition

The cognitive symptoms that someone with a major neurocognitive


disorder has may be reported by the person having them, someone close
to them, or a medical professional.

Medical professionals can assess a person’s cognitive abilities using


standardized neurological and psychological tests.

Mild neurocognitive disorder is a less severe form of major neurocognitive


disorder. The difference in symptoms is that if you have a mild
neurocognitive disorder, there’s only a modest cognitive decline from your
previous level of performance.

If you have a mild neurocognitive disorder, you can still perform daily
activities with independence. You can complete your usual complex
activities, although they may require more effort than before.
The DSM-5 discusses groups of symptoms that individuals with major and
mild neurocognitive disorders may have. Common symptoms among
neurocognitive disorders include:

● anxiety
● depression
● elation
● agitation
● confusion
● insomnia (difficulty sleeping)
● hypersomnia (oversleeping)
● apathy
● wandering
● disinhibition
● hyperphagia (extreme hunger or eating)
● hoarding
● hallucinations
● delusions

Treatment for major neurocognitive disorder is primarily based on what


symptoms you’re experiencing. For example, cognitive behavioral therapy
(CBT) can help treat symptoms of anxiety and depression present with
major neurocognitive disorder.

NCD DUE TO Alzheimer’s Disease

https://courses.lumenlearning.com/wm-abnormalpsych/chapter/neurocogni
tive-disorder-due-to-alzheimers-disease/#:~:text=The%20most%20commo
n%20early%20symptom,%2Dcare%2C%20and%20behavioral%20issues.
Frontotemporal DEMENTIA

https://www.nia.nih.gov/health/frontotemporal-disorders/what-are-frontote
mporal-disorders-causes-symptoms-and-treatment#:~:text=Frontotempora
l%20disorders%20(FTD)%2C%20sometimes,work%2C%20or%20difficulty
%20with%20walking.

key differences between Frontotemporal Dementia (FTD) and

Alzheimer's Disease:

1. Age of Onset:
● Alzheimer's Disease typically occurs later in life, usually
after the age of 65, although early-onset forms can
occur.
● FTD often presents at a younger age, typically between
40 and 65 years old, although it can occur at older ages
as well.

2. Symptom Presentation:
● Alzheimer's Disease commonly presents with memory
loss as a primary symptom, along with progressive
cognitive decline affecting various domains such as
language, visuospatial skills, and executive function.
● FTD typically presents with changes in behavior,
personality, and language skills, rather than memory
loss. Behavioral symptoms may include disinhibition,
apathy, social withdrawal, and inappropriate behaviors.
Language symptoms may include difficulties with speech
production or comprehension.

3. Neuroanatomical Changes:
● In Alzheimer's Disease, neurodegeneration primarily
affects the hippocampus and other regions of the
temporal and parietal lobes, which are associated with
memory and higher cognitive functions.
● In FTD, neurodegeneration primarily affects the frontal
and temporal lobes, particularly the frontal cortex and
anterior temporal lobes, which are involved in behavior,
personality, and language.

4. Neuropathological Features:
● Alzheimer's Disease is characterized by the
accumulation of beta-amyloid plaques and tau protein
tangles in the brain.
● FTD is characterized by abnormal protein aggregates,
including tau, TDP-43, and FUS, which accumulate in
affected brain regions.

5. Rate of Progression:
● Alzheimer's Disease typically progresses gradually over
several years, with memory loss and cognitive decline
worsening over time.
● FTD may progress more rapidly, particularly in cases
where behavioral symptoms are prominent, although the
rate of progression can vary widely between individuals.

6. Familial Risk:
● While Alzheimer's Disease can have a genetic
component, with certain gene mutations increasing the
risk of developing the disease, it is generally not as
strongly hereditary as some forms of FTD.
● FTD can have a stronger familial component, with
certain gene mutations associated with familial forms of
the disease, such as mutations in the MAPT, GRN, and
C9orf72 genes.

Overall, while both Alzheimer's Disease and FTD are

neurodegenerative disorders that lead to cognitive decline, they

have distinct clinical presentations, neuroanatomical patterns, and

underlying neuropathological features. Proper diagnosis by a

qualified healthcare professional is essential for appropriate

management and treatment planning.


Dementia With Lewy Bodies

Cognitive Symptoms

● DLB Presentation:
● Early onset of dementia, often accompanied by visual
hallucinations.
● Extrapyramidal motor symptoms akin to Parkinson's
Disease (PD) often arise concurrently or shortly after
dementia onset.
● Progressive Cognitive Decline:
● Cognitive decline typically begins early, often after age
55.
● Initial cognitive domains affected may vary, with
impairment in attention, executive function, and
visual-spatial skills being common.
● Early difficulties in multitasking, maintaining
conversations, and occasional navigation problems (e.g.,
getting lost while driving) may manifest.
● Short-term memory loss is notable, often reflecting
retrieval issues rather than encoding deficits seen in
Alzheimer's Disease (AD).
● Memory Impairment:
● Short-term memory loss significant, resembling
hippocampal-dependent memory encoding deficits in
AD.
● However, in DLB, short-term memory loss often stems
from retrieval problems, potentially improved with cues.
● Progression of Cognitive Impairment:
● Cognitive deficits worsen over time, spreading to affect
additional cognitive domains.
● When cognitive impairments impact social or
occupational functioning, meeting criteria for dementia
diagnosis.
Neuropsychiatric Symptoms

● Visual Hallucinations:
● Recurrent and complex visual hallucinations are
common in DLB, often appearing early in the disease
course.
● Hallucinations typically involve well-formed and animate
figures such as adults, children, deceased family
members, or animals.
● Initially, hallucinations are usually unimodal, lacking
sound, smell, or touch, and may be emotionally neutral
or occasionally dysphoric/fear-provoking.
● Distinguishable from visual illusions where objects are
misinterpreted, common particularly in dimly lit
environments.
● Delusions:
● Delusions may develop later in the disease progression,
often with a paranoid quality.
● Common delusions include infidelity, house intruders,
and theft, often resulting in misplaced items around the
home.
● Capgras syndrome may occur, where patients believe
familiar individuals, like spouses or caregivers, have
been replaced by imposters due to loss of emotional
associations with memories.
● Fluctuations of Attention and Arousal:
● Attention and alertness can fluctuate, leading to
episodes of staring, disrupted flow of ideas, or daytime
drowsiness and frequent naps.
● These fluctuations need differentiation from other causes
like medication side effects or infections.
● The Dementia Cognitive Fluctuation Scale, which
aggregates prior scales, can help assess fluctuations,
requiring positive responses to specific questions
regarding coherence of thoughts, daytime sleep,
drowsiness, and ease of arousal.

● Parkinsonian Motor Signs:


● Parkinsonian motor signs often develop concurrently
with or after cognitive symptoms in DLB.
● These signs may include bradykinesia and gait
impairment, which are more common than rest tremor.
● Motor presentation can vary widely, from classic
asymmetric pill-rolling tremor to clear extrapyramidal
dysfunction without motor concerns.
● Unlike PD, patients with DLB often have a limited
response to PD medications like carbidopa/levodopa,
despite reduced dopamine transporter activity on
imaging.
● Generalized myoclonus can also occur in some DLB
patients.
● Neuroleptic Sensitivity:
● Patients with DLB are particularly sensitive to
neuroleptics due to dopamine cell loss.
● Neuroleptics can trigger or worsen parkinsonism and
may lead to irreversible effects.
● Increased mortality risk and neuroleptic malignant
syndrome are associated with neuroleptic use in DLB.
● Neuroleptics can also worsen cognition, impair attention
and alertness, necessitating caution in their use.
● Other Associated Symptoms:
● Common symptoms shared with PD include rapid eye
movement (REM) sleep behavior disorder, loss of
olfaction, and constipation, which may precede DLB
onset by several years.
● Patients with DLB may report chronic high sensitivity to
medications.
● Autonomic impairment is present but less profound than
in multiple system atrophy (MSA), with constipation,
orthostatic hypotension, syncope, falls, and neurogenic
urinary symptoms being common.
● Diagnostic Criteria:
● Core features include recurrent visual hallucinations,
fluctuations in attention/alertness, and parkinsonian
motor signs.
● Supportive features include REM sleep behavior
disorder, severe neuroleptic sensitivity, or low dopamine
transporter uptake on imaging.
● Clinically probable DLB requires at least two core
features or one core feature and one supportive feature,
while clinically possible DLB requires only one core
feature.
● Specificity of the criteria is high, but sensitivity can be
low, suggesting the need for further refinement.

Distinguishing between dementia with Lewy bodies (DLB) and


Parkinson's disease dementia (PDD) :

1. Onset and Presentation:


● DLB typically presents with cognitive impairment, visual hallucinations,
and fluctuating attention early in the disease course, often preceding or
occurring simultaneously with parkinsonism.
● PDD primarily manifests with motor symptoms consistent with
Parkinson's disease (PD), such as bradykinesia, rigidity, and tremor,
with cognitive decline developing later in the disease course.
2. Timing of Cognitive Symptoms:
● In DLB, cognitive symptoms, including memory impairment, attention
deficits, and executive dysfunction, are prominent and often precede or
coincide with motor symptoms.
● In PDD, cognitive decline occurs later in the disease process, typically
after the onset of motor symptoms associated with PD.
3. Visual Hallucinations:
● Visual hallucinations are a hallmark feature of DLB and often occur
early in the disease course.
● While visual hallucinations can also occur in PDD, they are less
common and usually develop later in the disease progression.
4. Fluctuations in Attention and Alertness:
● Fluctuations in attention and alertness are characteristic of DLB and
may include periods of lucidity followed by confusion or drowsiness
throughout the day.
● These fluctuations are less pronounced in PDD, where cognitive decline
tends to be more steady and progressive.
5. Response to Parkinsonian Medications:
● Patients with DLB often have a limited response to medications
commonly used to treat motor symptoms in PD, such as levodopa, and
may experience worsening of cognitive symptoms or hallucinations.
● In contrast, patients with PDD typically show some improvement in
motor symptoms with dopaminergic medications, although cognitive
decline may continue.
6. Neuroimaging Findings:
● Both DLB and PDD may show reduced dopamine transporter uptake on
single-photon emission computed tomography (SPECT) or positron
emission tomography (PET) imaging, reflecting dopaminergic
dysfunction.
● However, DLB may exhibit more widespread cortical Lewy body
pathology on neuroimaging compared to PDD.
7. Neuroleptic Sensitivity:
● Patients with DLB are particularly sensitive to neuroleptic medications,
which can exacerbate parkinsonism and cognitive symptoms, and may
increase mortality risk.
● Neuroleptic sensitivity is less commonly observed in PDD.

Overall, while there is overlap between DLB and PDD in terms of clinical features and
underlying pathology, the timing and prominence of cognitive symptoms, presence of
visual hallucinations, fluctuations in attention, response to medication, and
neuroimaging findings can help differentiate between the two disorders. However, a
comprehensive clinical evaluation, including neuroimaging and neuropsychological
testing, is often necessary for an accurate diagnosis.

Parkinson's Disease and Dementia


https://www.hopkinsmedicine.org/health/conditions-and-diseases/parkinso
ns-disease/parkinsons-disease-and-dementia

dementia due to traumatic brain injury

https://www.webmd.com/alzheimers/dementia-head-injury

Vascular Dementia
https://www.nia.nih.gov/health/vascular-dementia/vascular-dementia-caus
es-symptoms-and-treatments

differentiate between the various types of

neurocognitive disorders:

1. Alzheimer's Disease (AD):


● Cause: Alzheimer's disease is primarily caused by the
accumulation of beta-amyloid plaques and tau tangles in
the brain.
● Symptoms: Initial symptoms often include memory loss,
confusion, and difficulty with language. As the disease
progresses, individuals may experience disorientation,
behavioral changes, and challenges with basic tasks.
● Progression: Alzheimer's disease typically progresses
slowly over several years, leading to severe cognitive
decline and functional impairment.
● Diagnosis: Diagnosis is based on clinical evaluation,
cognitive testing, brain imaging (e.g., MRI, PET scans),
and exclusion of other causes of dementia.
● Treatment: Treatment may include medications to
manage symptoms (e.g., cholinesterase inhibitors,
memantine) and supportive care.
2. Vascular Dementia:
● Cause: Vascular dementia results from impaired blood
flow to the brain, often due to strokes, small vessel
disease, or other vascular conditions.
● Symptoms: Symptoms can vary widely depending on the
location and severity of brain damage but may include
memory loss, difficulty with executive function, and mood
changes.
● Progression: The progression of vascular dementia may
be stepwise, with symptoms worsening after each stroke
or vascular event.
● Diagnosis: Diagnosis involves assessing vascular risk
factors, cognitive testing, brain imaging to identify
vascular lesions, and ruling out other causes of cognitive
decline.
● Treatment: Treatment focuses on managing vascular risk
factors (e.g., hypertension, diabetes), preventing further
strokes, and addressing cognitive symptoms.
3. Lewy Body Dementia (LBD):
● Cause: Lewy body dementia is characterized by the
presence of Lewy bodies (abnormal protein deposits) in
the brain, which disrupt neurotransmitter function.
● Symptoms: Common symptoms include visual
hallucinations, fluctuating cognition, parkinsonism
(tremors, stiffness), and REM sleep behavior disorder.
● Progression: Lewy body dementia tends to progress
gradually, with cognitive decline and motor symptoms
worsening over time.
● Diagnosis: Diagnosis is based on clinical features,
including the presence of core and supportive features
outlined in diagnostic criteria, as well as brain imaging.
● Treatment: Management may involve medications to
alleviate symptoms (e.g., cholinesterase inhibitors,
dopamine agonists) and supportive care.
4. Frontotemporal Dementia (FTD):
● Cause: Frontotemporal dementia is caused by
degeneration of the frontal and temporal lobes of the
brain, leading to changes in behavior, personality, and
language.
● Symptoms: Symptoms may include changes in behavior
(e.g., disinhibition, apathy), language difficulties (e.g.,
aphasia), and executive dysfunction.
● Progression: Frontotemporal dementia typically
progresses gradually, with symptoms worsening over
time and eventual decline in overall functioning.
● Diagnosis: Diagnosis involves clinical evaluation,
cognitive testing, and brain imaging to assess patterns of
brain atrophy.
● Treatment: Treatment focuses on managing symptoms,
behavioral interventions, and supportive care.
5. Parkinson's Disease Dementia (PDD):
● Cause: Parkinson's disease dementia occurs as a
complication of Parkinson's disease, with cognitive
decline developing in individuals with existing
Parkinson's symptoms.
● Symptoms: Symptoms may include cognitive
impairment, visual hallucinations, and motor symptoms
characteristic of Parkinson's disease (e.g., tremors,
rigidity).
● Progression: Cognitive decline in Parkinson's disease
dementia typically occurs later in the disease course,
with symptoms worsening gradually.
● Diagnosis: Diagnosis involves clinical assessment,
cognitive testing, and exclusion of other causes of
dementia in individuals with Parkinson's disease.
● Treatment: Treatment may involve medications to
manage Parkinson's symptoms and cognitive
impairment, as well as supportive care.

Each type of neurocognitive disorder has its own distinct features,

underlying causes, progression, diagnostic criteria, and

management strategies. Proper diagnosis and management require

careful evaluation by healthcare professionals with expertise in

neurocognitive disorders.

You might also like